3
Participants
Start Date
September 30, 2013
Primary Completion Date
November 30, 2015
Study Completion Date
November 30, 2015
Vemurafenib
Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
Icahn School of Medicine at Mount Sinai, New York
Collaborators (1)
Genentech, Inc.
INDUSTRY
Philip Friedlander
OTHER